Aflac (AFL) just opened Q1 2026 earnings season with a reference point of Q4 2025 revenue of US$4.9b, basic EPS of US$2.65 and net income of US$1.4b, setting the tone for how investors will assess the new numbers. The company has seen revenue move from US$5.4b in Q4 2024 to US$4.9b in Q4 2025, while basic EPS shifted from US$3.44 to US$2.65 over the same period, a pattern that puts the focus squarely on how efficiently that top line is being converted into profit. With net profit margin over the last year sitting below the prior year and a combined ratio in the mid 60% range on a trailing basis, this latest update lands in a context where investors are paying close attention to how resilient Aflac's margins really are.

See our full analysis for Aflac.

With the headline figures set, the next step is to see how these results line up against the widely followed narratives about Aflac's growth, risks and profitability to reveal which views hold up and which need a rethink.

Margins Slip From 28.8% To 21.2%

• Over the last year, Aflac's net profit margin moved from 28.8% to 21.2%, while trailing five year earnings declined about 5.5% annually.
• Consensus narrative talks about product upgrades and digital tools in Japan and the U.S. supporting long term income growth, yet the lower 21.2% margin and negative recent earnings trend show that higher tech and distribution spending has not yet translated into margin expansion.
  • Japan related expenses, including higher technology and other costs, have been flagged as contributing to higher expense ratios, which lines up with the drop from 28.8% to 21.2%.
  • At the same time, efforts like new cancer products and digital underwriting are intended to broaden the customer base, so readers may want to watch whether margins stabilize around the current 21.2% level or shift again as those products mature.

2.1% Revenue Growth Versus 11% Market

• Revenue growth over the last year averaged 2.1% per year, compared with the cited broader US market benchmark of 11% per year, while analysts are assuming about 1.5% annual revenue growth over the next 3 years.
• Bulls point to broader product ranges and more digital distribution as drivers for long term topline growth, but the current 2.1% revenue growth and guidance for 1.5% annual growth indicate a pace that trails the 11% market benchmark.
  • Management has acknowledged that net earned premiums in Japan are expected to decline 1% to 2%, which directly contrasts with the bullish claim that Japan product launches alone can push growth meaningfully higher.
  • In the U.S., sales were described as only 2.7% higher year over year, which is closer to the recent 2.1% group revenue growth than to the higher growth implied by the bullish story of expanded digital channels and partnerships.

On these growth figures, bulls and bears are really debating how much patience is required for the new products and channels to show up in revenues in a bigger way, and you can see both sides in the 🐂 Aflac Bull Case

DCF Fair Value US$180.25 Vs P/E Of 16.1x

• Aflac is trading at a P/E of 16.1x versus a cited US insurance industry average of 11.7x and peer average of 14.1x, while the provided DCF fair value is US$180.25 compared with a current share price of US$113.67.
• Bears focus on slower earnings trends and margin compression, arguing that a 16.1x P/E is high relative to peers, yet the DCF fair value of US$180.25 and a 2.15% dividend yield sit alongside trailing year earnings that were weaker than the prior five year trend.
  • The gap between the US$113.67 price and the US$180.25 DCF fair value suggests one set of numbers sees more long term cash flow support than the recent 5.5% annual EPS decline and 21.2% margin might imply.
  • At the same time, the analyst price target provided is US$112.21, almost in line with the current price, which gives bears a reference point that is much closer to recent earnings and profit margin trends than the DCF fair value estimate.

If you are weighing whether the recent margin and earnings figures matter more than the long term cash flow estimate, it helps to see how the cautious narrative frames that trade off in detail in the 🐻 Aflac Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Aflac on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Balancing those risks and rewards can feel complex, so it helps to look at the underlying data and decide what matters most for your own goals. To see the key issues investors are watching on both sides of the debate, start with the 2 key rewards and 1 important warning sign

See What Else Is Out There

Aflac's softer 2.1% revenue growth, margin slip from 28.8% to 21.2%, and trailing earnings decline highlight how results are lagging both peers and optimistic narratives.

If that mix of slower growth and compressed margins has you questioning the current P/E, you may wish to compare it with companies screened as 51 high quality undervalued stocks to see where the numbers look more compelling.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.